Healthy soft drinks specialist Coldpress has announced capital investment of £2.3 million from Odexia and investment banking and corporate finance business Marechale Capital.
The investment, which purchased a significant minority stake (20%) of Coldpress, was made up from £1 million from each company, plus £300,000 from high net worth clients.
“The welcome approach of Odexia and Marechale underpins the significant and sustainable success our vibrant drinks business has enjoyed both at home and abroad in recent months,” says Coldpress founder Andrew Gibb. “We feel now is the perfect moment to forge ahead, expand our sales and marketing function, accelerate our unrivalled innovation pipeline and open up other influential distribution channels.”
Commenting on the move, Odexia’s co-founder Carl Atkinson said he was impressed by Coldpress. “Odexia was especially encouraged by Coldpress’s robust financials that are all too rare among ambitious, modern-day growth companies,” he said. “It’s a well-managed operation that sits comfortably amongst our growing family of opinion-forming disruptor brands.”
Patrick Booth-Clibborn, CEO of Marechale Capital – a joint venture partner with Odexia’s Consumer Brand Fund – says: “Coldpress is the dominant brand in the European cold-pressed juice market and we’re pleased to have provided our investor clients with such a dynamic and innovative brand investment. At Marechale we are fortunate to have advised and financed some of the UK’s leading consumer and leisure brands, and we are delighted to have backed Andrew, one the leading voices within the cold pressed drinks sector, and his dynamic team.”